StreetInsider.com News Articles

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

Fri, 24 Jul 2026 16:01:00 -0400

BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 2026. The Company will host a conference call and webcast at 9:00 a.m. Eastern Daylight Time to discuss the results and current business trends.

To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q2 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presentation will be referenced during the webcast and will be posted to the Company’s website

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

Fri, 24 Jul 2026 16:01:00 -0400

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

Fri, 24 Jul 2026 16:01:00 -0400

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

Fri, 24 Jul 2026 16:01:00 -0400

Form 4 BRUKER CORP For: Jul 15 Filed by: Munch Mark

Thu, 16 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260716/26779862.html

Form 4 BRUKER CORP For: Jul 15 Filed by: Munch Mark

Thu, 16 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260716/26779862.html

Form 144 BRUKER CORP Filed by: Munch Mark

Wed, 15 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260715/26774262.html

Form 144 BRUKER CORP Filed by: Munch Mark

Wed, 15 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260715/26774262.html

Bruker acquires DISQVER blood infection detection platform

Wed, 15 Jul 2026 07:00:37 -0400

Bruker Corporation (Nasdaq: BRKR) has acquired the DISQVER® clinical metagenomics platform from Noscendo GmbH, adding metagenomic next-generation sequencing (mNGS) capabilities to its infection diagnostics portfolio, according to a press release.

The DISQVER® platform analyzes whole genome sequencing data directly from cell-free DNA in blood samples without prior cultivation, screening for more than 11,000 microbes and parasites in less than 24 hours after sample receipt. The technology is intended for use in research related to bloodstream infections, sepsis, endocarditis, and other severe infectious diseases.

Following the acquisition, DISQVER® remains available for research use only. Bruker stated it is pursuing registration of the platform

Bruker acquires DISQVER blood infection detection platform

Wed, 15 Jul 2026 07:00:37 -0400

Following the acquisition, DISQVER® remains available for research use only. Bruker stated it is pursuing registration of the platform

Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood

Wed, 15 Jul 2026 07:00:00 -0400

BREMEN, Germany--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715763519/en/

The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samples

DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis

Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood

Wed, 15 Jul 2026 07:00:00 -0400

BREMEN, Germany--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715763519/en/

The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samples

DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis

Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood

Wed, 15 Jul 2026 07:00:00 -0400

BREMEN, Germany--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715763519/en/

The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samples

DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis

Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood

Wed, 15 Jul 2026 07:00:00 -0400

BREMEN, Germany--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715763519/en/

The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samples

DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis

Guggenheim Reiterates Buy Rating on Bruker (BRKR)

Mon, 13 Jul 2026 06:53:02 -0400

Guggenheim analyst Subbu Nambi reiterated a Buy rating and $70.00 price target on Bruker (NASDAQ: BRKR).

The analyst commented: "After the bolus of investor interest in BRKR's semi growth opportunity, we spoke with several semiconductor experts with 135+ combined years of experience at leading foundries, IDMs, OSATs, and metrology equipment vendors to get to the bottom of it. Additionally, we include a primer on what BRKR has in their portfolio and comments from management that help frame business sizing today. We conclude there is line of sight to strong near-term demand that can scale, likely bringing ~30% metrology growth next year,

Form 3 BRUKER CORP For: Jul 01 Filed by: Pusch Wolfgang

Fri, 10 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260710/26757620.html

Form 3 BRUKER CORP For: Jul 01 Filed by: Pusch Wolfgang

Fri, 10 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260710/26757620.html

Bruker (BRKR) PT Raised to $60 at Citi

Wed, 08 Jul 2026 05:47:26 -0400

Citi analyst Patrick Donnelly raised the price target on Bruker (NASDAQ: BRKR) to $60.00 (from $44.00) while maintaining a Neutral rating.

Bruker (BRKR) PT Raised to $70 at Leerink

Tue, 07 Jul 2026 06:19:50 -0400

Leerink analyst Puneet Souda raised the price target on Bruker (NASDAQ: BRKR) to $70.00 (from $60.00) while maintaining a Outperform rating.

The analyst comments "In this report we investigate BRKR's recent AI trade (BRKR shares up ~66% over the last 3 months vs. S&P 500 +14%, LST peer group up ~20%) driven by their semi-exposed businesses (~$350M sales, ~9-10% of BRKR); semi metro has seen orders up 20%+ in 4Q25 and 1Q26. While one can argue that AI upside has mostly been captured within BRKR multiple at this point (~15x 2027E EV/ EBITDA vs. peer group ~17-18x), we still see room

Bruker (BRKR) PT Raised to $70 at Leerink

Tue, 07 Jul 2026 06:19:50 -0400

Leerink analyst Puneet Souda raised the price target on Bruker (NASDAQ: BRKR) to $70.00 (from $60.00) while maintaining a Outperform rating.

Bruker (BRKR) PT Raised to $70 at Guggenheim

Mon, 29 Jun 2026 06:55:01 -0400

Guggenheim analyst Subbu Nambi raised the price target on Bruker (NASDAQ: BRKR) to $70.00 (from $50.00) while maintaining a Buy rating.

Bruker (BRKR) PT Raised to $60 at Barclays

Wed, 24 Jun 2026 02:59:10 -0400

Barclays analyst Luke Sergott raised the price target on Bruker (NASDAQ: BRKR) to $60.00 (from $53.00) while maintaining a Overweight rating.

Form 4 BRUKER CORP For: Jun 15 Filed by: Munch Mark

Tue, 16 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260616/26654279.html

Form 4 BRUKER CORP For: Jun 15 Filed by: Munch Mark

Tue, 16 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260616/26654279.html

Form 144 BRUKER CORP Filed by: Munch Mark

Mon, 15 Jun 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260615/26648007.html